Jasper Therapeutics Stock Jumps on Positive Asthma Drug Results
Jasper Therapeutics (JSPR) shares rise 60% after experimental drug briquilimab shows promising results in early-stage asthma study, improving lung function and reducing inflammation.
/ 911 items
#Healthcare↓
TD Cowen Starts Coverage on C4 Therapeutics with a Buy Rating
TD Cowen initiates C4 Therapeutics with a Buy rating, highlighting its strong clinical validation in targeted protein degradation and the potential of Cemsi as a "backbone therapy" for multiple myeloma.
Janux's Prostate Cancer Drug Shows Declining Response Rates in Early Trial Data
Janux Therapeutics' (JANX) JANX007 immunotherapy disappoints with only 30% response rate in heavily pre-treated prostate cancer patients, raising concerns about efficacy.
FDA Memo on Vaccine Deaths Sends Moderna, Novavax Stocks Tumbling
Moderna and Novavax shares drop 5-6% after FDA's vaccine chief links COVID-19 shots to 10 children's deaths and announces stricter vaccine approval standards.
MAIA Biotech CEO & Directors Buy 182K Shares
MAIA Biotechnology's CEO and board members purchased 182,445 shares in late November 2025, signaling strong confidence in their cancer drug development program.
KALA BIO Receives $6M Investment and Appoints New CEO
KALA BIO secures $6M investment from David E. Lazar, names him CEO and Chairman, and plans to continue developing eye disease therapies after CHASE trial setbacks.